Alumis files for IPO ahead of Phase 3 studies for second-gen TYK2 inhibitor

Amber Tong

Precision immunology startup Alumis has filed to go public, pitching itself to Wall Street just three months after raising $259 million from private investors. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Alumis files for IPO ahead of Phase 3 studies for second-gen TYK2 inhibitor

Amber Tong

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

Teva launches Stelara biosimilar at 85% discount as wider field emerges

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Alu­mis files for IPO ahead of Phase 3 stud­ies for sec­ond-gen TYK2 in­hibitor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Alumis files for IPO ahead of Phase 3 studies for second-gen TYK2 inhibitor